Drug-eluting stents in patients with chronic kidney disease: A prospective registry study

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Shenoy, Chetan ^a   Boura, Judy ^b   Orshaw, Pamela ^a   Harjai, Kishore J ^a  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CREATININE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BARE METAL STENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; REGISTER; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; CHRONIC KIDNEY FAILURE; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICS; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649746212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015070     Document Type: Article

References (33)

1. Widimsky P, Rychlik I (2010) Renal disease and acute coronary syndrome. Heart 96: 86-92.
2. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, et al. (2009) The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53: 2129-2140.
3. U.S. Renal Data System USRDS (2009) Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350: 221-231.
6. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, et al. (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119: 3198-3206.
7. Coca SG, Krumholz HM, Garg AX, Parikh CR (2006) Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296: 1377-1384.
8. Novak JE, Szczech LA (2008) Feast and famine: epidemiology and clinical trials in chronic kidney disease. J Am Soc Nephrol 19: 2-4.
9. Himmelfarb J (2007) Chronic kidney disease and the public health: gaps in evidence from interventional trials. JAMA 297: 2630-2633.
10. Harjai KJ, Shenoy C, Orshaw P, Boura J (2009) Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 95: 1579-1586.
11. Shenoy C, Orshaw P, Devarakonda S, Harjai KJ (2009) Occurrence, predictors, and outcomes of post-percutaneous coronary intervention thrombocytopenia in an unselected population. J Interv Cardiol 22: 156-162.
12. National Cardiovascular Data Registry DED, Technology Downloads and Risk Adjustment Available at: http://www.ncdr.com/WebNCDR/elements.aspx. Last accessed August 18, 2010.
13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
14. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147.
15. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, et al. (2008) Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 51: 991-996.
16. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, et al. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020-1029.
17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047.
18. Appleby CE, Ivanov J, Lavi S, Mackie K, Horlick EM, et al. (2009) The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv 2: 309-316.
19. Zhang R, Ni J, Zhang J, Hu J, Yang Z, et al. (2006) Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. Chin Med J (Engl) 119: 1176-1181.
20. Ishio N, Kobayashi Y, Takebayashi H, Iijima Y, Kanda J, et al. (2007) Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 71: 1525-1529.
21. Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, et al. (2007) Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv 69: 808-814.
22. Spaulding C, Rosencher J, Varenne O (2010) Use of drug eluting stents in ST segment elevation myocardial infarction. Heart 96: 1073-1077.
23. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, et al. (2006) Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119: 1056-1061.
24. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, et al. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus baremetal stents. J Am Coll Cardiol 48: 2584-2591.
25. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, et al. (2007) Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50: 463-470.
26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370: 937-948.
27. Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, et al. (2009) Drugeluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2: 285-293.
28. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130.
29. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, et al. (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108-1113.
30. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, et al. (2005) Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUSIV Trial. Am Heart J 150: 1163-1170.
31. Okada T, Hayashi Y, Toyofuku M, Imazu M, Otsuka M, et al. (2008) One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting coronary stents. Circ J 72: 1430-1435.
32. King SB, 3rd, Smith SC, Jr., Hirshfeld JW, Jr., Jacobs AK, Morrison DA, et al. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117: 261-295.
33. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, et al. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49: 1982-1988.